PTC Therapeutics Inc
NASDAQ:PTCT

Watchlist Manager
PTC Therapeutics Inc Logo
PTC Therapeutics Inc
NASDAQ:PTCT
Watchlist
Price: 40.69 USD 0.07% Market Closed
Market Cap: 3.1B USD
Have any thoughts about
PTC Therapeutics Inc?
Write Note

Intrinsic Value

PTCT's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one PTCT stock under the Base Case scenario is 45.38 USD. Compared to the current market price of 40.69 USD, PTC Therapeutics Inc is Undervalued by 10%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

PTCT Intrinsic Value
45.38 USD
Undervaluation 10%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
PTC Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for PTCT cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about PTCT?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about PTC Therapeutics Inc

Provide an overview of the primary business activities
of PTC Therapeutics Inc.

What unique competitive advantages
does PTC Therapeutics Inc hold over its rivals?

What risks and challenges
does PTC Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in PTC Therapeutics Inc recently?

Summarize the latest earnings call
of PTC Therapeutics Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for PTC Therapeutics Inc.

Provide P/S
for PTC Therapeutics Inc.

Provide P/E
for PTC Therapeutics Inc.

Provide P/OCF
for PTC Therapeutics Inc.

Provide P/FCFE
for PTC Therapeutics Inc.

Provide P/B
for PTC Therapeutics Inc.

Provide EV/S
for PTC Therapeutics Inc.

Provide EV/GP
for PTC Therapeutics Inc.

Provide EV/EBITDA
for PTC Therapeutics Inc.

Provide EV/EBIT
for PTC Therapeutics Inc.

Provide EV/OCF
for PTC Therapeutics Inc.

Provide EV/FCFF
for PTC Therapeutics Inc.

Provide EV/IC
for PTC Therapeutics Inc.

Show me price targets
for PTC Therapeutics Inc made by professional analysts.

What are the Revenue projections
for PTC Therapeutics Inc?

How accurate were the past Revenue estimates
for PTC Therapeutics Inc?

What are the Net Income projections
for PTC Therapeutics Inc?

How accurate were the past Net Income estimates
for PTC Therapeutics Inc?

What are the EPS projections
for PTC Therapeutics Inc?

How accurate were the past EPS estimates
for PTC Therapeutics Inc?

What are the EBIT projections
for PTC Therapeutics Inc?

How accurate were the past EBIT estimates
for PTC Therapeutics Inc?

Compare the revenue forecasts
for PTC Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of PTC Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of PTC Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of PTC Therapeutics Inc compared to its peers.

Compare the P/E ratios
of PTC Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing PTC Therapeutics Inc with its peers.

Analyze the financial leverage
of PTC Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for PTC Therapeutics Inc.

Provide ROE
for PTC Therapeutics Inc.

Provide ROA
for PTC Therapeutics Inc.

Provide ROIC
for PTC Therapeutics Inc.

Provide ROCE
for PTC Therapeutics Inc.

Provide Gross Margin
for PTC Therapeutics Inc.

Provide Operating Margin
for PTC Therapeutics Inc.

Provide Net Margin
for PTC Therapeutics Inc.

Provide FCF Margin
for PTC Therapeutics Inc.

Show all solvency ratios
for PTC Therapeutics Inc.

Provide D/E Ratio
for PTC Therapeutics Inc.

Provide D/A Ratio
for PTC Therapeutics Inc.

Provide Interest Coverage Ratio
for PTC Therapeutics Inc.

Provide Altman Z-Score Ratio
for PTC Therapeutics Inc.

Provide Quick Ratio
for PTC Therapeutics Inc.

Provide Current Ratio
for PTC Therapeutics Inc.

Provide Cash Ratio
for PTC Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for PTC Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for PTC Therapeutics Inc?

What is the current Free Cash Flow
of PTC Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for PTC Therapeutics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
PTC Therapeutics Inc

Current Assets 1.4B
Cash & Short-Term Investments 1.1B
Receivables 187.2m
Other Current Assets 77.5m
Non-Current Assets 558.4m
PP&E 123.1m
Intangibles 412.2m
Other Non-Current Assets 23.1m
Current Liabilities 609.8m
Accounts Payable 128.6m
Accrued Liabilities 86.7m
Other Current Liabilities 394.6m
Non-Current Liabilities 2.3B
Long-Term Debt 2.1B
Other Non-Current Liabilities 156.5m
Efficiency

Earnings Waterfall
PTC Therapeutics Inc

Revenue
900.5m USD
Cost of Revenue
-68.9m USD
Gross Profit
831.6m USD
Operating Expenses
-1B USD
Operating Income
-196.3m USD
Other Expenses
-283.3m USD
Net Income
-479.5m USD

Free Cash Flow Analysis
PTC Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

PTC Therapeutics reported strong performance in Q2 2024, with revenue hitting $187 million, anchored by $118 million from their Duchenne Muscular Dystrophy (DMD) franchise. This consistent success led the company to revise their 2024 revenue guidance to between $700 million and $750 million. The sale of their gene therapy manufacturing business generated $27.5 million in upfront cash, allowing further strategic financial maneuvers. PTC's global plans include the planned 2025 launch of sepiapterin for PKU, supported by strong clinical data, and the continued advancement of therapies for Huntington's disease, Friedreich ataxia, and ALS.

What is Earnings Call?
Fundamental Scores

PTCT Profitability Score
Profitability Due Diligence

PTC Therapeutics Inc's profitability score is 35/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional ROE
Exceptional 3-Years Revenue Growth
ROE is Increasing
35/100
Profitability
Score

PTC Therapeutics Inc's profitability score is 35/100. The higher the profitability score, the more profitable the company is.

PTCT Solvency Score
Solvency Due Diligence

PTC Therapeutics Inc's solvency score is 36/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Positive Net Debt
Long-Term Solvency
36/100
Solvency
Score

PTC Therapeutics Inc's solvency score is 36/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

PTCT Price Targets Summary
PTC Therapeutics Inc

Wall Street analysts forecast PTCT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PTCT is 40.96 USD with a low forecast of 26.26 USD and a high forecast of 67.2 USD.

Lowest
Price Target
26.26 USD
35% Downside
Average
Price Target
40.96 USD
1% Upside
Highest
Price Target
67.2 USD
65% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for PTCT?

Click here to dive deeper.

Dividends

PTC Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for PTCT is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

PTCT Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

PTC Therapeutics Inc Logo
PTC Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

3.1B USD

Dividend Yield

0%

Description

PTC Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and commercialization of clinically differentiated medicines. The company is headquartered in South Plainfield, New Jersey and currently employs 1,252 full-time employees. The company went IPO on 2013-06-20. The Company’s portfolio pipeline includes several commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases. The firm has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD). The Company’s gene therapy platform focuses on the development of therapies for rare and debilitating diseases of the nervous system (CNS). The Company’s splicing platform focuses on the development of therapies for diseases, such as SMA, that involve regulation of messenger RNA (mRNA) splicing in the cell.

Contact

NEW JERSEY
South Plainfield
100 Corporate Ct
+19082227000.0
www.ptcbio.com

IPO

2013-06-20

Employees

1 252

Officers

See Also

Discover More
What is the Intrinsic Value of one PTCT stock?

The intrinsic value of one PTCT stock under the Base Case scenario is 45.38 USD.

Is PTCT stock undervalued or overvalued?

Compared to the current market price of 40.69 USD, PTC Therapeutics Inc is Undervalued by 10%.

Back to Top